Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) has been awarded a $9.4 million subcontract in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices for treating hormone disorders under ARPA-H's REACT program. The BIO-INSYNC project focuses on creating implantable devices that can produce therapeutic molecules and monitor disease biomarkers in real-time for at least one year after implantation.

The initiative will initially target thyroid disorders, developing systems to measure thyroid hormone levels and produce required doses. Patients and healthcare providers will be able to monitor and control the treatment via smartphone. The project combines Ginkgo's expertise in mammalian cell and iPSC engineering with Carnegie Mellon's bioelectronics capabilities, along with researchers from the University of Pittsburgh, University of Florida, and UC Santa Cruz.

Positive

• Secured $9.4 million in funding through ARPA-H subcontract
• Partnership with prestigious academic institutions expands market reach
• Development of innovative long-term implantable treatment solutions

Negative

• Project success and commercial viability remain uncertain
• Long development timeline before potential revenue generation

Insights

Biotech Research Analyst

The $9.4 million ARPA-H award represents a significant validation of Ginkgo's cell engineering capabilities in the emerging bioelectronics field. The focus on developing implantable cell-based devices for hormone disorders addresses a substantial market opportunity, particularly in thyroid disorders and diabetes. The project's ambitious goal of creating devices that function for over a year could potentially disrupt the $28 billion global hormone replacement therapy market.

The collaboration with Carnegie Mellon University strengthens Ginkgo's position in translational research and expands their capabilities in iPSC engineering. While the monetary value is modest relative to Ginkgo's scale, the strategic importance lies in demonstrating their platform's versatility and potential for therapeutic applications. This could open doors to larger commercial partnerships in the cell therapy space.

Medical Device Expert

The BIO-INSYNC project represents a pioneering approach in bioelectronic medicine, combining cell therapy with smart device technology. The smartphone-controlled monitoring and drug delivery system could revolutionize chronic disease management, particularly for the millions affected by thyroid disorders. The one-year functionality target is ambitious but achievable given current advances in implantable technology.

The integration of real-time biomarker monitoring with automated hormone production could significantly improve treatment precision and patient compliance. However, regulatory approval for such novel combination products will be complex, requiring extensive safety and efficacy data. Success here could establish a new paradigm for treating other endocrine disorders.

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders

BOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program. Ginkgo is eligible to receive up to $9.4 million for its work across the program.

Chronic diseases that require continuous monitoring and treatment, such as thyroid disorders, diabetes, and obesity affect millions globally, presenting a significant public health challenge. Through this collaboration, Ginkgo will leverage its industry-leading capabilities in mammalian cell engineering and induced pluripotent stem cell (iPSC) engineering to create cells that produce and deliver therapeutic molecules—such as hormones—and/or monitor the disease status.

The Biointegrated Implantable Systems for Cell-based Sensing and Therapy (BIO-INSYNC) project focuses on implantable bioelectronic devices that utilize engineered cells to produce therapeutic molecules on demand and/or to measure disease biomarkers in real time. These devices are expected to function for at least a year after implantation. The team will demonstrate their platform technology using thyroid disorders, including hypo- and hyperthyroidism, as sample diseases. The systems will measure the levels of thyroid hormones and/or produce the required dose of thyroid hormones. The patient and the healthcare provider can monitor disease and control drug delivery status remotely using a smartphone.

"This is an exciting opportunity to support Carnegie Mellon's team on ARPA-H's REACT program," said Jesse Dill, Business Development Lead at Ginkgo Bioworks. "Chronic diseases that require continuous management cause a high public health burden, and bioelectronic devices like those targeted in the REACT program have the potential to unlock new, convenient ways to monitor and treat these conditions. We are excited to apply our expertise in mammalian cell engineering and iPSC-derived tissue differentiation to this challenge, in partnership with our team members."

Mike Nehil, Senior Director of Mammalian Engineering at Ginkgo Bioworks, added, "Our advanced capabilities in mammalian cell engineering make us a strong partner for academic-led teams aiming to push the boundaries of medical innovation. We look forward to contributing to this significant project and advancing our iPSC platform."

"We are thrilled to partner with Ginkgo Bioworks on this groundbreaking initiative," said Dr. Burak Ozdoganlar, Ver Planck Endowed Chair Professor of Mechanical Engineering at Carnegie Mellon University, who leads the BIO-INSYNC project. "By combining our expertise in bioelectronics and tissue engineering with Ginkgo's leading cell engineering platform, we aim to create transformative therapies that could redefine the management of hormone disorders. This multidisciplinary project will also include researchers from the University of Pittsburgh, University of Florida, and University of California—Santa Cruz."

This partnership underscores Ginkgo's commitment to collaborating with academic institutions and innovative funding agencies to address complex health challenges. By participating in this groundbreaking program, Ginkgo plans to further develop and demonstrate its capabilities in engineering mammalian cell systems to treat complex diseases.

To learn more about how you can bring innovative biological solutions to life, please visit our page for Ginkgo Cell Therapy Services.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly report on Form 10-Q, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-awarded-9-4-million-in-partnership-with-carnegie-mellon-university-to-develop-implantable-cell-based-bioelectronic-devices-for-disease-treatment-under-arpa-hs-react-program-302333762.html

SOURCE Ginkgo Bioworks

FAQ

What is the value of Ginkgo Bioworks' (DNA) ARPA-H contract for bioelectronic devices?

Ginkgo Bioworks is eligible to receive up to $9.4 million for its work on the REACT program in partnership with Carnegie Mellon University.

What medical conditions will Ginkgo Bioworks' (DNA) BIO-INSYNC project initially target?

The BIO-INSYNC project will initially target thyroid disorders, including hypo- and hyperthyroidism, developing systems to measure and produce thyroid hormones.

How long are Ginkgo Bioworks' (DNA) implantable bioelectronic devices expected to function?

The bioelectronic devices are expected to function for at least one year after implantation.

Which universities are collaborating with Ginkgo Bioworks (DNA) on the BIO-INSYNC project?

The project includes researchers from Carnegie Mellon University, University of Pittsburgh, University of Florida, and University of California—Santa Cruz.

How will patients monitor their treatment using Ginkgo Bioworks' (DNA) bioelectronic devices?

Patients and healthcare providers will be able to monitor disease status and control drug delivery remotely using a smartphone.